Bridgebio Oncology Therapeutics Inc (BBOT)

$10.15 +0.17 (1.70%)
Market Cap 798.29M
Revenue (ttm) 0.00
Net Income (ttm) -74.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 359,400
Avg Vol 287,130
Day's Range N/A - N/A
Shares Out 79.99M
Stochastic %K 7%
Beta 0.12
Analysts Strong Sell
Price Target $25.12

Company Profile

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide 3-kinase malignancies. The company's product pipeline includes BBO-8520, a direct inhibitor targeting the on and off states of KRAS that is in Phase I clinical trial to treat patients with KRASG12C mutant non-small cell lung cancer; and BBO-10203, an orally bioavailable small molecule that is in Phase I cl...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 405 4770
Website: bbotx.com
Address:
256 E. Grand Avenue, Suite 104, South San Francisco, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 23 at 1:17 AM
$BBOT RSI: 36.15, MACD: -0.4482 Vol: 1.03, MA20: 11.51, MA50: 11.88 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
topstockalerts
topstockalerts Feb. 11 at 7:50 PM
$BBOT Setting up nicely for continuation. Price is consolidating near highs. That often leads to another push 🚀.
0 · Reply
BishopDorothea
BishopDorothea Feb. 11 at 2:08 PM
$BBOT Update: Stifel Initiates Buy, PT $23 Key Highlights: ▪️ BBO-8520: Potential best-in-class KRAS G12C inhibitor for NSCLC. Targets ON/OFF states → improved therapeutic index vs 1st-gen inhibitors. ▪️ BBO-10203: PI3Kα:RAS “breaker” → could be a blockbuster combination backbone across multiple indications. ▪️ Mechanism: Tackles PI3Kα/RAS signaling that drives resistance to RAS inhibitors in RAS-mutant cancers. Novel oncology approaches = serious long-term potential. Keep an eye on $BBOT.
0 · Reply
Quantumup
Quantumup Feb. 10 at 9:29 PM
Stifel🏁 $BBOT Buy-$23 and said, We initiate coverage of BridgeBio Oncology Therapeutics (BBOT) with a Buy rating and $23 Target Price. $RVMD $MRK $BBIO Stifel added, While oncology investors crave novel mechanisms, they often balk at early stage companies where biology remains clinically unproven. BBOT is in the sweet spot by targeting RAS and PI3Ka-the two most commonly mutated oncogenes—using unique mechanistic approaches that address the safety and resistance hurdles of earlier generation drugs. With early de-risking data presented in January 2026 and a cash runway into 2028, BBOT is well-positioned ahead of numerous clinical catalysts in 2H26.
0 · Reply
Quantumup
Quantumup Feb. 10 at 12:38 PM
William Blair🏁 $TYRA Outperform-$59.62 FVE and said that it sees three blockbuster opportunities for pot'ly first-in-class dabogratinib. $URGN $BBOT $MRK ALPMY BMRN $LLY BMY ACRV JNJ Here's what else William Blair had to say: We are initiating coverage of Tyra Biosciences with an Outperform rating and $59.62 fair-value estimate. Tyra is developing dabogratinib, a potentially first-in-class, selective FGFR3 inhibitor that could have broad therapeutic potential in oncology and growth disorders. The company has generated early clinical data with dabogratinib in metastatic urothelial carcinoma (mUC), establishing proof of concept of its clinical activity and improved safety profile relative to pan-FGFR inhibitors.
0 · Reply
Quantumup
Quantumup Feb. 9 at 1:58 PM
Stifel reit'd $ERAS Buy-$10 & provided its takeaways after🗣️w/ CFO/CBO. $RVMD $BBOT $DAWN MRK NVS $IMRX We hosted a fireside chat with Erasca's CFO/CBO David Chacko during the 2026 Stifel Biotech Ski Summit in Park Clty (February 2-4). See main takeaways below: panRAS competitive landscape — why hasn't pharma brought forward a pan-RAS? ERAS views RVMD as a trailblazer with themselves solidly in second place; secured COM in 10/2025. ERAS-0015 is optimized for PK and potency; competitors who enhance one over the other could see diminishing returns (e.g. less favorable therapeutic index). The tri-complex chemistry and IP make it very difficult to bring forward a novel pan-RAS — a lot easier to make a new pan-KRAS. ERAS is very complimentary of the medicinal chemistry heavy lifting of WuXi who discovered ERAS-0015. Competition from China is less of a concern for pan-RAS molecular glues — 'never say never', but do not expect a surge of Chinese 'me too' assets we saw with the KRAS G12C class.
0 · Reply
TheQuantMachine
TheQuantMachine Feb. 4 at 3:15 PM
$BBOT is a robotics and automation company; it is a pre-profitability story dependent on securing large deployment contracts and scaling its technology.
0 · Reply
Irish_lass
Irish_lass Jan. 27 at 9:39 PM
$BBOT
0 · Reply
Quantumup
Quantumup Jan. 27 at 1:01 PM
Guggenheim⬆️the PT on $ERAS to $12 from $5 and reiterated at a Buy rating. $RVMD $IMRX $BBOT MRK $DAWN NVS Guggenheim said in its note: We are updating our ERAS model and PT, reflecting recent updates provided on ERAS-0015 (pan-RAS) and ERAS-4001 (pan-KRAS), as well as the recently announced financing. We now incorporate 30% PoS-adjusted revenue estimates for ERAS-0015 in 2L+ NSCLC and PDAC and a 2030 estimated commercial launch. Next up, ERAS plans to present initial Phase 1 monotherapy data on ERAS-0015 in patients with RAS-mutant solid tumors in 1H26 and initiate monotherapy expansion cohorts and combination dose escalation cohorts in 2H26. ERAS-4001 Phase 1 data will be presented in 2H26, per ERAS. Our PT moves to $12/diluted share (from $5).
0 · Reply
Quantumup
Quantumup Jan. 27 at 11:40 AM
Oppenheimer⬆️ $RVMD's PT to $150, reit'd at OP/said, RVMD has been the subject of substantial M&A speculation entering 2026 as we see multiple milestones this year that could sweeten a potential deal (see additional discussion below). $MRK $IMRX $BBOT $ERAS Oppenheimer added, Our biotech M&A analysis shows increasing strategic demand for novel approaches to areas of high unmet need while oncology remains dominant, supporting RVMD as an attractive potential takeout candidate. Although news sources suggested Merck is no longer in talks to acquire RVMD, we think the update could reflect management's confidence in delivering multiple catalysts for substantial value creation, and we believe RVMD's current share price (RVMD: -17% vs. NBI: +0.4% on 1/26) should open an attractive entry point. We remain buyers ahead of a potentially transformative year for RVMD, and raise our PT to $150 from $75.
0 · Reply
Latest News on BBOT
BBOT to Participate in Upcoming Investor Healthcare Conferences

Feb 12, 2026, 4:05 PM EST - 11 days ago

BBOT to Participate in Upcoming Investor Healthcare Conferences

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Feb 11, 2026, 4:05 PM EST - 12 days ago

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Oncology Therapeutics, Inc. (BBOT) Discusses Clinical Data Updates for BBO-8520, BBO-11818, and BBO-10203 Transcript

Jan 13, 2026, 12:16 PM EST - 5 weeks ago

BridgeBio Oncology Therapeutics, Inc. (BBOT) Discusses Clinical Data Updates for BBO-8520, BBO-11818, and BBO-10203 Transcript

BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs

Jan 7, 2026, 7:00 AM EST - 6 weeks ago

BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs

BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 16, 2025, 4:05 PM EST - 2 months ago

BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference

BridgeBio Oncology Therapeutics: Promising KRAS Drug Developer - In My View, At Least

Dec 12, 2025, 5:32 PM EST - 2 months ago

BridgeBio Oncology Therapeutics: Promising KRAS Drug Developer - In My View, At Least

BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Dec 11, 2025, 4:05 PM EST - 2 months ago

BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)

Dec 10, 2025, 4:05 PM EST - 2 months ago

BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)

BBOT to Participate in Upcoming December Investor Healthcare Conferences

Nov 18, 2025, 4:05 PM EST - 3 months ago

BBOT to Participate in Upcoming December Investor Healthcare Conferences

BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

Nov 12, 2025, 4:05 PM EST - 3 months ago

BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

HLXB

BBOT to Participate in the Jefferies Global Healthcare Conference in London

Nov 3, 2025, 4:05 PM EST - 4 months ago

BBOT to Participate in the Jefferies Global Healthcare Conference in London

BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)

Oct 30, 2025, 5:45 PM EDT - 4 months ago

BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia

Oct 25, 2025, 12:30 PM EDT - 4 months ago

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia

BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 23, 2025, 4:05 PM EDT - 4 months ago

BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 4:05 PM EDT - 4 months ago

BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

BBOT to Participate in Upcoming September Investor Healthcare Conferences

Aug 20, 2025, 8:00 AM EDT - 6 months ago

BBOT to Participate in Upcoming September Investor Healthcare Conferences

BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition

Aug 11, 2025, 4:30 PM EDT - 7 months ago

BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition

HLXB

OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 23 at 1:17 AM
$BBOT RSI: 36.15, MACD: -0.4482 Vol: 1.03, MA20: 11.51, MA50: 11.88 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
topstockalerts
topstockalerts Feb. 11 at 7:50 PM
$BBOT Setting up nicely for continuation. Price is consolidating near highs. That often leads to another push 🚀.
0 · Reply
BishopDorothea
BishopDorothea Feb. 11 at 2:08 PM
$BBOT Update: Stifel Initiates Buy, PT $23 Key Highlights: ▪️ BBO-8520: Potential best-in-class KRAS G12C inhibitor for NSCLC. Targets ON/OFF states → improved therapeutic index vs 1st-gen inhibitors. ▪️ BBO-10203: PI3Kα:RAS “breaker” → could be a blockbuster combination backbone across multiple indications. ▪️ Mechanism: Tackles PI3Kα/RAS signaling that drives resistance to RAS inhibitors in RAS-mutant cancers. Novel oncology approaches = serious long-term potential. Keep an eye on $BBOT.
0 · Reply
Quantumup
Quantumup Feb. 10 at 9:29 PM
Stifel🏁 $BBOT Buy-$23 and said, We initiate coverage of BridgeBio Oncology Therapeutics (BBOT) with a Buy rating and $23 Target Price. $RVMD $MRK $BBIO Stifel added, While oncology investors crave novel mechanisms, they often balk at early stage companies where biology remains clinically unproven. BBOT is in the sweet spot by targeting RAS and PI3Ka-the two most commonly mutated oncogenes—using unique mechanistic approaches that address the safety and resistance hurdles of earlier generation drugs. With early de-risking data presented in January 2026 and a cash runway into 2028, BBOT is well-positioned ahead of numerous clinical catalysts in 2H26.
0 · Reply
Quantumup
Quantumup Feb. 10 at 12:38 PM
William Blair🏁 $TYRA Outperform-$59.62 FVE and said that it sees three blockbuster opportunities for pot'ly first-in-class dabogratinib. $URGN $BBOT $MRK ALPMY BMRN $LLY BMY ACRV JNJ Here's what else William Blair had to say: We are initiating coverage of Tyra Biosciences with an Outperform rating and $59.62 fair-value estimate. Tyra is developing dabogratinib, a potentially first-in-class, selective FGFR3 inhibitor that could have broad therapeutic potential in oncology and growth disorders. The company has generated early clinical data with dabogratinib in metastatic urothelial carcinoma (mUC), establishing proof of concept of its clinical activity and improved safety profile relative to pan-FGFR inhibitors.
0 · Reply
Quantumup
Quantumup Feb. 9 at 1:58 PM
Stifel reit'd $ERAS Buy-$10 & provided its takeaways after🗣️w/ CFO/CBO. $RVMD $BBOT $DAWN MRK NVS $IMRX We hosted a fireside chat with Erasca's CFO/CBO David Chacko during the 2026 Stifel Biotech Ski Summit in Park Clty (February 2-4). See main takeaways below: panRAS competitive landscape — why hasn't pharma brought forward a pan-RAS? ERAS views RVMD as a trailblazer with themselves solidly in second place; secured COM in 10/2025. ERAS-0015 is optimized for PK and potency; competitors who enhance one over the other could see diminishing returns (e.g. less favorable therapeutic index). The tri-complex chemistry and IP make it very difficult to bring forward a novel pan-RAS — a lot easier to make a new pan-KRAS. ERAS is very complimentary of the medicinal chemistry heavy lifting of WuXi who discovered ERAS-0015. Competition from China is less of a concern for pan-RAS molecular glues — 'never say never', but do not expect a surge of Chinese 'me too' assets we saw with the KRAS G12C class.
0 · Reply
TheQuantMachine
TheQuantMachine Feb. 4 at 3:15 PM
$BBOT is a robotics and automation company; it is a pre-profitability story dependent on securing large deployment contracts and scaling its technology.
0 · Reply
Irish_lass
Irish_lass Jan. 27 at 9:39 PM
$BBOT
0 · Reply
Quantumup
Quantumup Jan. 27 at 1:01 PM
Guggenheim⬆️the PT on $ERAS to $12 from $5 and reiterated at a Buy rating. $RVMD $IMRX $BBOT MRK $DAWN NVS Guggenheim said in its note: We are updating our ERAS model and PT, reflecting recent updates provided on ERAS-0015 (pan-RAS) and ERAS-4001 (pan-KRAS), as well as the recently announced financing. We now incorporate 30% PoS-adjusted revenue estimates for ERAS-0015 in 2L+ NSCLC and PDAC and a 2030 estimated commercial launch. Next up, ERAS plans to present initial Phase 1 monotherapy data on ERAS-0015 in patients with RAS-mutant solid tumors in 1H26 and initiate monotherapy expansion cohorts and combination dose escalation cohorts in 2H26. ERAS-4001 Phase 1 data will be presented in 2H26, per ERAS. Our PT moves to $12/diluted share (from $5).
0 · Reply
Quantumup
Quantumup Jan. 27 at 11:40 AM
Oppenheimer⬆️ $RVMD's PT to $150, reit'd at OP/said, RVMD has been the subject of substantial M&A speculation entering 2026 as we see multiple milestones this year that could sweeten a potential deal (see additional discussion below). $MRK $IMRX $BBOT $ERAS Oppenheimer added, Our biotech M&A analysis shows increasing strategic demand for novel approaches to areas of high unmet need while oncology remains dominant, supporting RVMD as an attractive potential takeout candidate. Although news sources suggested Merck is no longer in talks to acquire RVMD, we think the update could reflect management's confidence in delivering multiple catalysts for substantial value creation, and we believe RVMD's current share price (RVMD: -17% vs. NBI: +0.4% on 1/26) should open an attractive entry point. We remain buyers ahead of a potentially transformative year for RVMD, and raise our PT to $150 from $75.
0 · Reply
zount82
zount82 Jan. 26 at 2:33 AM
$BBOT Merck no longer in talks to buy $RVMD https://www.wsj.com/health/pharma/merck-no-longer-in-talks-to-buy-revolution-medicines-b8d5e5eb?mod=mhp sorry it's behind a paywall. 😕
1 · Reply
SuperGreenToday
SuperGreenToday Jan. 23 at 8:08 PM
$BBOT
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 19 at 9:50 PM
$BBOT RSI: 42.87, MACD: -0.1134 Vol: 0.54, MA20: 12.17, MA50: 12.33 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Quantumup
Quantumup Jan. 12 at 3:25 PM
Truist reiterated $RVMD Buy-$99 and said: $28-$32 Billion Is Closer To What We Think RVMD Would Find Appealing $MRK $BBOT $ERAS AMGN BMY $IMTX Truist added: We think RVMD remains in a position of strength, and doesn't need to do a deal. If RVMD is getting bought out in the near term, we think it would be for an offer that was difficult to refuse, and we think the range suggested in the Financial Times article ($28-$32 billion) is more in the vicinity of that number. A bid from Merck (MRK, NR) could make sense, in our view, providing antitrust conditions are met (see below). But at this price range, we think a potential acquirer would want to see some Phase 3 data to de-risk Daraxon - either topline data from RASolute-302 (potentially due in 1H26, we think), or perhaps an interim look at this same study (which we think could have happened, or will happen soon).
0 · Reply
Quantumup
Quantumup Jan. 9 at 1:02 PM
Raymond James🏁 $BBOT $RVMD MRK $BBIO spinout RJ: We are initiating coverage of BridgeBio Oncology (BBOT) with an Outperform rating and a price target price of $24. Our rating is based on four points: 1) We see the preliminary activity and safety profile of BBO-8520, a KRAS G12C selective inhibitor, observed in a Phase 1 NSCLC trial as promising. BBO-8520 is poised to become a new contender in the 1L NSCLC setting with pembrolizumab combination data as well. 2) The company's pan-KRAS inhibitor, BBO-11818, has a broad and potent inhibitory activity while avoiding NRAS/HRAS inhibition with early signals of dose response. 3) We view the RAS:PI3Ka breaker, BBO-10203, as a unique angle to break into metastatic breast cancer that can potentially evolve into a differentiated drug class pending initial Phase 1 combination results in 2H 2026. 4) The company is well capitalized to get through proof of concept updates for all assets. Our confidence is tempered by crowding in the KRAS inhibitor field.
0 · Reply
Quantumup
Quantumup Jan. 8 at 5:41 PM
BofA⬆️Top Pick $RVMD's PT to $109 from $98, reiterated at Buy, +⬆️dara's PoS in 1L PDAC to 65% from 60%, in NSCLC from 40% to 50% in 1L &⬆️zoldonrasib's PoS in 1L to 55% from 45% & 2L PDAC to 50% from 40% & to 50% from 40% in 2L+ NSCLC after the Tx received BTD in this setting $BBOT $ERAS $IMRX $AMGN BMY Here's what BofA had to say in its note to investors:
1 · Reply
Quantumup
Quantumup Jan. 8 at 1:22 PM
Stifel y'day reiterated $RVMD Buy-$85, w/ PT under review. $BBOT $ERAS $IMRX BMY $AMGN Stifel said~News regarding ABBV being in advanced talks to acquire RVMD was circulating this afternoon - this news was later refuted by ABBV, but we have gotten a lot of questions on what take out valuation could make sense for RVMD. We were surprised by the timing of this speculation, given that RVMD management has recently given the impression that they intend to remain independent near term. However, if it were to be acquired at this stage, we think RVMD could easily go in the $30B+ range. Our target price and rating are currently under review as we further evaluate impact of this RVMD M&A speculation; our current target price does not factor in an M&A premium.
1 · Reply
TheBullishTrade
TheBullishTrade Jan. 7 at 8:01 PM
$BBOT BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs Wednesday, 7th January at 7:00 am BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients eligible for 6-month follow-up remaining on treatment for ≥6 months, alongside a potentially differentiated safety profile. Encouraging early efficacy signals were seen in patients with KRASG12C and STK11 and/or KEAP1 co-mutants, where all five initial patients achieved partial response. BBO-8520 in combination with pembrolizumab, at active dose levels, demonstrated promising efficacy data and a distinct, differentiated safety profile. A favorable liver safety profile was observed compared with pembrolizumab monotherapy. BBO-11818 monotherapy demonstrated a confirmed partial response (PR) in pancreatic cancer and anti-tumor activity was observed across dose levels and tumor types with tumor reductions at higher dose levels with a generally favorable, differentiated safety profile in dose escalation. BBO-10203 demonstrated a potentially differentiated safety profile without any observed events of hyperglycemia and without any enrollment restrictions on baseline HbA1c and glucose levels; combination studies with standard-of-care (SOC) treatments in colorectal cancer (CRC) and breast cancer (BC) have been initiated; internal combination studies with BBO-8520 and BBO-11818 are anticipated to open this year. Company webcast to be held today at 8:30 a.m. Eastern Time (ET).
0 · Reply
prismmarketview
prismmarketview Jan. 7 at 6:13 PM
$BBOT ’s ON/OFF Biology: A Game-Changer in Oncology https://prismmarketview.com/bbots-on-off-biology-a-game-changer-in-oncology/
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 31 at 3:58 PM
$BBOT Current Stock Price: $12.59
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 31 at 12:25 AM
$BBOT Current Stock Price: $12.31
0 · Reply
BundleBaron
BundleBaron Dec. 26 at 9:14 AM
$BBOT Macro trends are relevant, yet internal execution remains the decisive catalyst. Margins must remain resilient as activity scales. Visible traction across indicators would support the story. Without confirmation, volatility likely persists.
0 · Reply